ECF506

• Description:

  ECF506 (NXP900) is a highly potent and orally active YES1/SRC kinase inhibitor with an IC50 of 0.47 nM. eCF506 locks its target into its native “closed” conformation, thereby inhibiting both kinase activity and complex formation with protein partners. eCF506 can be used for the study of esophageal squamous cancer and breast cancer[1].

• Product Name Alternative:

  NXP900

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H317, H318, H334, H335, H341, H361, H370, H413

• Target:

  Src

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/eCF506.html

• Concentration:

  10mM

• Purity:

  99.77

• Solubility:

  DMSO : 62.5 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic)

• Smiles:

  NC1=C2C (C3=CC (OC) =C (NC (OC (C) (C) C) =O) C=C3) =NN (CCN4CCC (N (C) C) CC4) C2=NC=N1

• Molecular Formula:

  C26H38N8O3

• Molecular Weight:

  510.63

• Precautions:

  H315, H317, H318, H334, H335, H341, H361, H370, H413

• References & Citations:

  [1]Fraser C, et al. Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase. J Med Chem. 2016 May 26;59 (10) :4697-710.|[2]Authors: Sweta Dash, et al. Preclinical efficacy of NXP900, a YES1/SRC kinase inhibitor in esophageal squamous cancer models. Journal of Clinical Oncology. Volume 41, Number 16_suppl.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• CAS Number:

  1914078-41-3